Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Liraglutide and Liver Injury: Rare Case Report with Literature Review

Author(s): Amir Mohammad Salehi, Maryam Hasanzarrini*, Hossain Salehi and Ensiyeh Jenabi

Volume 24, Issue 6, 2024

Published on: 25 October, 2023

Page: [725 - 729] Pages: 5

DOI: 10.2174/0118715303180615231011053011

Price: $65

Abstract

Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus (T2DM). So far, few severe side effects have been reported for it.

Case Presentation: A 41-year-old woman was admitted to the Emergency Room with diffuse abdominal pain. The patient had a known case of T2DM, fatty liver disease, and hypertension and was treated with Metformin, Liraglutide, and Losartan. Her liver functional test (LFT) was consistent with hepatocellular injury; however, laboratory tests and abdominal ultrasound were used to rule out autoimmune hepatitis. Due to concerns for drug-induced liver injury (DILL), liraglutide was discontinued and N-acetyl cysteine was prescribed. On the fifth day of hospitalization, the patient's symptoms resolved and his LFT started to decrease on the sixth day after 2 months, the patient's liver enzyme levels returned to normal.

Conclusion: Liraglutide is one of the most important drugs in the treatment of T2DM.The most common side effects of this drug are constipation, nausea, vomiting, diarrhea, indigestion, and loss of appetite. In rare cases, symptoms of thyroid cancer, pancreatitis, and hypoglycemia have been reported, however, DILL is one of the extremely rare side effect of Liraglutide. It is important to increase the awareness of physicians about the liver injury of Liraglutide.

Keywords: Liraglutide, Drug-induced liver injury, Type 2 diabetes mellitus, GLP-1, LFT, diarrhea, hypoglycemia.

« Previous
Graphical Abstract

[1]
Goyal, R.; Jialal, I.; Castano, M. Diabetes Mellitus Type 2 (Nursing); StatPearls Publishing: Florida, United States, 2021.
[2]
Olokoba, A.B.; Obateru, O.A.; Olokoba, L.B. Type 2 diabetes mellitus: A review of current trends. Oman Med. J., 2012, 27(4), 269-273.
[http://dx.doi.org/10.5001/omj.2012.68] [PMID: 23071876]
[3]
Parvataneni, S.; Ramachandran, R.; Then, E.; Grantham, T.; Gaduputi, V. An Exceedingly Rare Case of Liraglutide-Induced Liver Injury. Case Rep. Gastrointest. Med., 2021, 2021, 6306149.
[http://dx.doi.org/10.1155/2021/6306149]
[4]
Nagell, C.F.; Wettergren, A.; Ørskov, C.; Holst, J.J. Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand. J. Gastroenterol., 2006, 41(6), 667-672.
[http://dx.doi.org/10.1080/00365520500408253] [PMID: 16716964]
[5]
Andrade, R.J.; Chalasani, N.; Björnsson, E.S.; Suzuki, A.; Kullak-Ublick, G.A.; Watkins, P.B.; Devarbhavi, H.; Merz, M.; Lucena, M.I.; Kaplowitz, N.; Aithal, G.P. Drug-induced liver injury. Nat. Rev. Dis. Primers, 2019, 5(1), 58.
[http://dx.doi.org/10.1038/s41572-019-0105-0] [PMID: 31439850]
[6]
Abboud, G.; Kaplowitz, N. Drug-induced liver injury. Drug Saf., 2007, 30(4), 277-294.
[http://dx.doi.org/10.2165/00002018-200730040-00001] [PMID: 17408305]
[7]
Leise, M.D.; Poterucha, J.J.; Talwalkar, J.A., Eds.; Drug-induced liver injury. Mayo clinic proceedings; Elsevier: Amsterdam, 2014.
[8]
Danan, G.; Teschke, R. RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci., 2015, 17(1), 14.
[http://dx.doi.org/10.3390/ijms17010014] [PMID: 26712744]
[9]
Teschke, R.; Eickhoff, A.; Schwarzenboeck, A.; Schmidt-Taenzer, W.; Genthner, A.; Frenzel, C. Clinical review: Herbal hepatotoxicity and the call for systematic data documentation of individual cases. J. Liver Clin. Res., 2015, 2, 1008.
[10]
Shetty, R.; Basheer, F.T.; Poojari, P.G.; Thunga, G.; Chandran, V.P.; Acharya, L.D. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab. Syndr., 2022, 16(3), 102427.
[http://dx.doi.org/10.1016/j.dsx.2022.102427] [PMID: 35217468]
[11]
Sisson, E.M. Liraglutide: Clinical pharmacology and considerations for therapy. Pharmacotherapy, 2011, 31(9), 896-911.
[http://dx.doi.org/10.1592/phco.31.9.896] [PMID: 21923591]
[12]
Kela, R.; Davies, M.J. Treatment evaluation of liraglutide in type 2 diabetes. Expert Opin. Biol. Ther., 2012, 12(11), 1551-1556.
[http://dx.doi.org/10.1517/14712598.2012.716823] [PMID: 22897447]
[13]
Singh, S.; Chang, H.Y.; Richards, T.M.; Weiner, J.P.; Clark, J.M.; Segal, J.B. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study. JAMA Intern. Med., 2013, 173(7), 534-539.
[http://dx.doi.org/10.1001/jamainternmed.2013.2720] [PMID: 23440284]
[14]
Egan, A.G.; Blind, E.; Dunder, K.; de Graeff, P.A.; Hummer, B.T.; Bourcier, T.; Rosebraugh, C. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N. Engl. J. Med., 2014, 370(9), 794-797.
[http://dx.doi.org/10.1056/NEJMp1314078] [PMID: 24571751]
[15]
Kern, E.; VanWagner, L.B.; Yang, G.Y.; Rinella, M.E. Liraglutide-induced autoimmune hepatitis. JAMA Intern. Med., 2014, 174(6), 984-987.
[http://dx.doi.org/10.1001/jamainternmed.2014.674] [PMID: 24733687]
[16]
Maor, Y.; Ergaz, D.; Malnick, S.D.H.; Melzer, E.; Neuman, M.G. Liraglutide-Induced Hepatotoxicity. Biomedicines, 2021, 9(2), 106.
[http://dx.doi.org/10.3390/biomedicines9020106] [PMID: 33498980]

Rights & Permissions Print Cite
Article Metrics
42
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy